LIVE
TMO
Thermo Fisher Scientific Inc. · Healthcare - Life Science Tools & Services
$464.61
+3.75% this month
VERSUS
⟷
COMPARE
A
Agilent Technologies, Inc. · Healthcare - Analytical Instruments
$127.06
+14.91% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
TMO
4
A
1
Comparison scoreboard
TMO LEADS 4/5AI Score
TMO ✓51.1
A 50.8
1Y Return
TMO ✓+19.05%
A +9.45%
Fwd P/E
TMO ✓17.22
A 19.65
Target Up.
TMO ✓+27.67%
A +23.50%
Op. Margin
TMO 17.89%
A ✓23.71%
Metrics last refreshed: 6/20/2026
Quick take
TMO vs A Stock Comparison: AI Score, Valuation, Performance and Upside
TMO (Thermo Fisher Scientific) is the global life science tools leader with unmatched breadth across instruments, reagents, and pharma services, while A (Agilent Technologies) is a focused analytical instruments specialist with leadership in chromatography, mass spectrometry, and genomics. Thermo Fisher is larger and more diversified; Agilent is more focused on analytical chemistry and materials characterization.
TMO vs A is life science tools scale leader (Thermo Fisher's end-to-end laboratory and pharma services platform) versus focused analytical instruments specialist (Agilent's LC/MS, genomics, and pathology for pharma, food, and environmental) — both essential life science tool suppliers with pharma spending exposure.
Live analysis · updated 6/20/2026
TMO holds the edge across 4 of 5 key metrics in this comparison. TMO leads on both 1-year return (+19.05%) and forward P/E (17.22x vs 19.65x for A), a relatively favorable combination of momentum and valuation. A leads on both revenue growth (10.00%) and operating margin (23.71%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for TMO (+27.67%) than for A (+23.50%).
Normalized 1Y performance
TMO
A
Recent returns
TMO
A
Analyst price targets & sentiment
TMO · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.6/5.0)
Price target range
analyst low$450.00
analyst high$767.00
analyst mean$599.19
current price$464.61
+27.7% upside to analyst mean
A
Price target range
analyst mean$160.35
current price$127.06
+23.5% upside to analyst mean
Who should consider this stock?
TMO may suit investors who:
- →Want the world's largest life science tools company with unparalleled product breadth, pharma services revenue through CDMO/CRO capabilities, and a long track record of value-creating acquisitions
- →Value Thermo Fisher's bioprocessing recovery as a catalyst for growth re-acceleration following the COVID normalization and biopharma inventory destocking cycle
- →Prefer maximum life science diversification across instruments, reagents, consumables, diagnostics, and pharma services from a single high-quality compounder
A may suit investors who:
- →Want focused analytical instruments exposure through Agilent's leadership in liquid chromatography, mass spectrometry, and genomics serving pharmaceutical, food, and environmental markets
- →Value Agilent's end market diversification (food safety, environmental testing, forensics) as a buffer against purely pharma-driven spending cycles
- →See Agilent's DAKO oncology pathology business as growing companion diagnostic and cancer biomarker testing revenues tied to personalized medicine adoption
Performance & AI score
| Metric | TMO | A |
|---|---|---|
| AI score | 51.1 | 50.8 |
| AI rank | #392 | #412 |
| Latest close | $464.61 | $127.06 |
| 1M return | +3.75% | +14.91% |
| 6M return | -17.41% | -7.02% |
| 1Y return | +19.05% | +9.45% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | TMO | A |
|---|---|---|
| 1Y ago | $11.84K (+18.4%) started 2025-06-18 | $11K (+10.0%) started 2025-06-18 |
| 5Y ago | $9.79K (-2.1%) started 2021-06-21 | $9.16K (-8.4%) started 2021-06-21 |
| 10Y ago | $32.85K (+228.5%) started 2016-06-20 | $31.81K (+218.1%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | TMO | A |
|---|---|---|
| Market cap | $174.42B | $36.67B |
| Trailing P/E | 25.77 | 26.02 |
| Forward P/E | 17.22 | 19.65 |
| Price/Sales | 3.54 | N/A |
| EV/Revenue | 4.75 | 5.31 |
| Analyst target | $599.19 | $160.35 |
| Target upside | +27.67% | +23.50% |
Growth, profitability & risk
| Metric | TMO | A |
|---|---|---|
| Revenue growth | 6.20% | 10.00% |
| Earnings growth | 11.30% | 60.00% |
| EPS growth | +11.30% | +60.00% |
| FCF margin | +12.21% | +12.87% |
| Operating margin | 17.89% | 23.71% |
| Profit margin | 15.15% | 19.55% |
| ROIC proxy | 13.52% | 21.33% |
| Return on equity | 13.52% | 21.33% |
| Dividend yield | 0.40% | 0.79% |
| Beta | 0.87 | 1.26 |
| Debt/equity | 82.90 | 49.73 |
| Current ratio | 1.53 | 2.10 |
| Quick ratio | 0.97 | 1.46 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
TMO max drawdown31.45%
A max drawdown29.87%
TMO max wkly drop11.02%
A max wkly drop8.22%
5Y risk snapshot
TMO max drawdown41.02%
A max drawdown43.19%
TMO max wkly drop13.18%
A max wkly drop14.03%
10Y risk snapshot
TMO max drawdown41.02%
A max drawdown43.19%
TMO max wkly drop13.18%
A max wkly drop21.18%
Performance metrics by period
| Period | Metric | TMO | A |
|---|---|---|---|
| 1Y | Growth | +18.35% | +9.99% |
| CAGR | +18.38% | +10.00% | |
| Sharpe ratio | 0.55 | 0.31 | |
| Max drawdown | 31.45% | 29.87% | |
| Max daily drop | 9.20% | 5.95% | |
| Max wkly drop | 11.02% | 8.22% | |
| 5Y | Growth | -3.02% | -10.87% |
| CAGR | -0.61% | -2.28% | |
| Sharpe ratio | -0.05 | -0.08 | |
| Max drawdown | 41.02% | 43.19% | |
| Max daily drop | 9.20% | 9.66% | |
| Max wkly drop | 13.18% | 14.03% | |
| 10Y | Growth | +220.72% | +195.65% |
| CAGR | +12.37% | +11.46% | |
| Sharpe ratio | 0.40 | 0.37 | |
| Max drawdown | 41.02% | 43.19% | |
| Max daily drop | 9.20% | 11.01% | |
| Max wkly drop | 13.18% | 21.18% |
Business comparison
| Category | TMO | A |
|---|---|---|
| Company | Thermo Fisher Scientific Inc. | Agilent Technologies, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | N/A |
| Core business | Thermo Fisher Scientific is the world's largest life science tools company, providing laboratory instruments, reagents, consumables, and CRO/CMO services for pharmaceutical and biotech drug development, research, clinical diagnostics, and environmental testing — operating as the essential supplier to life science research globally. | Agilent Technologies provides analytical instruments, consumables, software, and services for life science and applied markets — including liquid chromatography (LC), mass spectrometry (MS), gas chromatography (GC), spectroscopy, pathology (DAKO cancer diagnostics), and genomics (SureSelect) for pharma, food safety, environmental, and forensics customers. |
| Investor focus | Investors track Thermo Fisher's organic revenue growth (ex-COVID testing and vaccines), bioprocessing recovery, Life Science Solutions segment performance, pharma services (CDMO/CRO) bookings, and the company's capital allocation between acquisitions and buybacks. | Investors track Agilent's revenue by end market (pharma, food, environmental, forensics), instrument order trends, liquid chromatography and mass spectrometry market share, and margin efficiency. |
TMO strengths
- →Scale leadership as the world's largest life science tools company creates unique breadth advantage — researchers can source most laboratory needs from a single Thermo Fisher supplier relationship
- →Diversified across four segments (Life Science Solutions, Analytical Instruments, Laboratory Products & Services, Pharma Services) provides resilience when any single end market slows
- →Pharma services (PPD CRO, CDMO manufacturing) provides a fee-for-service recurring revenue stream less dependent on instrument purchase cycles
A strengths
- →Market-leading position in liquid chromatography (LC) and LC/MS instruments used extensively in pharmaceutical quality control and new drug development
- →Diversified end markets spanning pharma, food safety, environmental testing, and forensics provides resilience when any single end market slows — food and environmental testing are less correlated to pharma spending cycles
- →DAKO oncology pathology products provide diagnostics exposure to companion diagnostics and cancer biomarker testing as personalized medicine grows
Risks to watch — TMO
- →Biopharma funding environment affects instrument purchasing — when biotech funding is tight, smaller biotech companies reduce capital equipment purchases, affecting Thermo Fisher's instrument revenue
- →Post-COVID normalization created a significant air pocket in revenue — COVID testing, vaccine manufacturing, and pandemic-related demand was extraordinary and has since normalized sharply
- →Thermo Fisher's scale means acquisitions must be increasingly large to move the needle — smaller bolt-on acquisitions have less relative impact than on smaller peers
Risks to watch — A
- →Pharmaceutical market exposure means Agilent shares the same biopharma spending cycle risks as other life science tool companies — funding tightness affects instrument purchases
- →Competition from Waters Corporation in LC/MS and Bruker in mass spectrometry means Agilent must continuously invest in instrument performance to maintain market share
- →China represents a significant portion of Agilent revenue — geopolitical tensions, economic slowdown, and Chinese government buy-domestic preferences create headwinds for multinational lab instrument suppliers
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →